FDA to review naxitamab for use in neuroblastoma under priority review process

Regulatory review in the US of this GD2-targeted monoclonal antibody is intended to be complete by 30th November this year. It has orphan status in the EU, but a marketing authorisation application has not yet been forwarded to the EMA.


Biospace Inc.